305 related articles for article (PubMed ID: 11313828)
1. MHC class II presentation of endogenously expressed antigens by transfected dendritic cells.
Diebold SS; Cotten M; Koch N; Zenke M
Gene Ther; 2001 Mar; 8(6):487-93. PubMed ID: 11313828
[TBL] [Abstract][Full Text] [Related]
2. Retrovirally transduced bone marrow-derived dendritic cells require CD4+ T cell help to elicit protective and therapeutic antitumor immunity.
De Veerman M; Heirman C; Van Meirvenne S; Devos S; Corthals J; Moser M; Thielemans K
J Immunol; 1999 Jan; 162(1):144-51. PubMed ID: 9886380
[TBL] [Abstract][Full Text] [Related]
3. RNA-containing adenovirus/polyethylenimine transfer complexes effectively transduce dendritic cells and induce antigen-specific T cell responses.
Gust TC; Diebold SS; Cotten M; Zenke M
J Gene Med; 2004 Apr; 6(4):464-70. PubMed ID: 15079821
[TBL] [Abstract][Full Text] [Related]
4. Bacterial antigen delivery systems: phagocytic processing of bacterial antigens for MHC-I and MHC-II presentation to T cells.
Svensson M; Pfeifer J; Stockinger B; Wick MJ
Behring Inst Mitt; 1997 Feb; (98):197-211. PubMed ID: 9382741
[TBL] [Abstract][Full Text] [Related]
5. Active CD4+ helper T cells directly stimulate CD8+ cytotoxic T lymphocyte responses in wild-type and MHC II gene knockout C57BL/6 mice and transgenic RIP-mOVA mice expressing islet beta-cell ovalbumin antigen leading to diabetes.
Ye Z; Ahmed KA; Hao S; Zhang X; Xie Y; Munegowda MA; Meng Q; Chibbar R; Xiang J
Autoimmunity; 2008 Nov; 41(7):501-11. PubMed ID: 18855194
[TBL] [Abstract][Full Text] [Related]
6. Immunization with a lentiviral vector stimulates both CD4 and CD8 T cell responses to an ovalbumin transgene.
Rowe HM; Lopes L; Ikeda Y; Bailey R; Barde I; Zenke M; Chain BM; Collins MK
Mol Ther; 2006 Feb; 13(2):310-9. PubMed ID: 16275163
[TBL] [Abstract][Full Text] [Related]
7. Targeting glycan modified OVA to murine DC-SIGN transgenic dendritic cells enhances MHC class I and II presentation.
Singh SK; Stephani J; Schaefer M; Kalay H; García-Vallejo JJ; den Haan J; Saeland E; Sparwasser T; van Kooyk Y
Mol Immunol; 2009 Dec; 47(2-3):164-74. PubMed ID: 19818504
[TBL] [Abstract][Full Text] [Related]
8. Induction of antitumor immunity using bone marrow-generated dendritic cells.
Porgador A; Snyder D; Gilboa E
J Immunol; 1996 Apr; 156(8):2918-26. PubMed ID: 8609412
[TBL] [Abstract][Full Text] [Related]
9. Mouse Schwann cells activate MHC class I and II restricted T-cell responses, but require external peptide processing for MHC class II presentation.
Meyer zu Hörste G; Heidenreich H; Mausberg AK; Lehmann HC; ten Asbroek AL; Saavedra JT; Baas F; Hartung HP; Wiendl H; Kieseier BC
Neurobiol Dis; 2010 Feb; 37(2):483-90. PubMed ID: 19914379
[TBL] [Abstract][Full Text] [Related]
10. The class II MHC-restricted presentation of endogenously synthesized ovalbumin displays clonal variation, requires endosomal/lysosomal processing, and is up-regulated by heat shock.
Michalek MT; Benacerraf B; Rock KL
J Immunol; 1992 Feb; 148(4):1016-24. PubMed ID: 1737924
[TBL] [Abstract][Full Text] [Related]
11. Impaired ability of MHC class II-/- dendritic cells to provide tumor protection is rescued by CD40 ligation.
Hermans IF; Ritchie DS; Daish A; Yang J; Kehry MR; Ronchese F
J Immunol; 1999 Jul; 163(1):77-81. PubMed ID: 10384102
[TBL] [Abstract][Full Text] [Related]
12. Adenovirus vector-mediated overexpression of a truncated form of the p65 nuclear factor kappa B cDNA in dendritic cells enhances their function resulting in immune-mediated suppression of preexisting murine tumors.
Lee JM; Mahtabifard A; Yamada R; Crystal RG; Korst RJ
Clin Cancer Res; 2002 Nov; 8(11):3561-9. PubMed ID: 12429647
[TBL] [Abstract][Full Text] [Related]
13. Deoxyribonucleic acid (DNA) encoding a pan-major histocompatibility complex class II peptide analogue augmented antigen-specific cellular immunity and suppressive effects on tumor growth elicited by DNA vaccine immunotherapy.
Teramoto K; Kontani K; Ozaki Y; Sawai S; Tezuka N; Nagata T; Fujino S; Itoh Y; Taguchi O; Koide Y; Asai T; Ohkubo I; Ogasawara K
Cancer Res; 2003 Nov; 63(22):7920-5. PubMed ID: 14633722
[TBL] [Abstract][Full Text] [Related]
14. C-terminal extension of the MHC class II-associated invariant chain by an antigenic sequence triggers activation of naive T cells.
Sponaas A; Carstens C; Koch N
Gene Ther; 1999 Nov; 6(11):1826-34. PubMed ID: 10602378
[TBL] [Abstract][Full Text] [Related]
15. Effective induction of anti-tumor immune responses with oligomannose-coated liposome targeting to intraperitoneal phagocytic cells.
Ikehara Y; Shiuchi N; Kabata-Ikehara S; Nakanishi H; Yokoyama N; Takagi H; Nagata T; Koide Y; Kuzushima K; Takahashi T; Tsujimura K; Kojima N
Cancer Lett; 2008 Feb; 260(1-2):137-45. PubMed ID: 18077084
[TBL] [Abstract][Full Text] [Related]
16. Protein kinase C delta stimulates antigen presentation by Class II MHC in murine dendritic cells.
Majewski M; Bose TO; Sillé FC; Pollington AM; Fiebiger E; Boes M
Int Immunol; 2007 Jun; 19(6):719-32. PubMed ID: 17446207
[TBL] [Abstract][Full Text] [Related]
17. Fc epsilon receptor I on dendritic cells delivers IgE-bound multivalent antigens into a cathepsin S-dependent pathway of MHC class II presentation.
Maurer D; Fiebiger E; Reininger B; Ebner C; Petzelbauer P; Shi GP; Chapman HA; Stingl G
J Immunol; 1998 Sep; 161(6):2731-9. PubMed ID: 9743330
[TBL] [Abstract][Full Text] [Related]
18. An essential role of antigen-presenting cell/T-helper type 1 cell-cell interactions in draining lymph node during complete eradication of class II-negative tumor tissue by T-helper type 1 cell therapy.
Chamoto K; Wakita D; Narita Y; Zhang Y; Noguchi D; Ohnishi H; Iguchi T; Sakai T; Ikeda H; Nishimura T
Cancer Res; 2006 Feb; 66(3):1809-17. PubMed ID: 16452242
[TBL] [Abstract][Full Text] [Related]
19. Cloned dendritic cells can present exogenous antigens on both MHC class I and class II molecules.
Shen Z; Reznikoff G; Dranoff G; Rock KL
J Immunol; 1997 Mar; 158(6):2723-30. PubMed ID: 9058806
[TBL] [Abstract][Full Text] [Related]
20. Strategies for antigen choice and priming of dendritic cells influence the polarization and efficacy of antitumor T-cell responses in dendritic cell-based cancer vaccination.
Galea-Lauri J; Wells JW; Darling D; Harrison P; Farzaneh F
Cancer Immunol Immunother; 2004 Nov; 53(11):963-77. PubMed ID: 15146294
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
